The announcement of a class action lawsuit against Kyverna Therapeutics for alleged securities violations related to their IPO is likely to negatively impact investor sentiment and the stock price in the short term. Legal issues can lead to uncertainty and potential financial liabilities, which typically result in a negative market reaction.